Clinical trials: Spine Disease
Degenerative Disc Disease, Chronic Low-back Pain
Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy
This study will be a prospective, open-label, multi-center study that will collect safety data for the minimally invasive PerQdisc Nucleus Replacement Device deployed to reduce chronic low back pain.
- Trial name
- LOPAIN1 (NCT04141098)
- Testing
- All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
- Where
- Paraguay
- Volunteers
- 9 people
- Sponsor
- Spinal Stabilization Technologies
Ankylosing Spondylitis
A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)
This study will evaluate the effect and safety of 608 in patients with AS.
- Trial name
- NCT06242652
- Testing
- 608 Dose A, 608 Dose B, 608 Dose C
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Lumbar Spinal Stenosis, Degenerative Spondylolisthesis
A Pivotal Study of the Premia Spine TOPS™ System
The purpose of this trial is to assess whether the Total Posterior Spine System (TOPS System) is more effective than transforaminal lumbar interbody fusion (TLIF) when used to stabilize a single lumbar level (L2 - L5) following…
- Trial name
- NCT03012776
- Testing
- Total Posterior Spine System (TOPS), Transforaminal Lumbar Interbody Fusion (TLIF)
- Where
- 36 sites in United States
- Volunteers
- 305 people
- Sponsor
- Premia Spine
Ankylosing Spondylitis, Psoriatic Arthritis
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
This 12-month postmarketing observational study (PMOS) was a prospective, single-arm, multicenter, multi-country study, with follow-up visits at 3, 6, 9, and 12 months after the initial baseline visit.
- Trial name
- NCT01474876
- Volunteers
- 566 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis, specifically in improving signs and symptoms of psoriatic arthritis (tender and swollen…
- Trial name
- PALACE-1 (NCT01172938)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 504 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Ankylosing Spondylitis
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
This is an open-label, multicenter and observational study in China, which is designed to record the data of RA \& AS patients within 52 weeks after rheumatologists decided to prescribe etanercept, and evaluate the safety and…
- Trial name
- ENBREL NIS CN (NCT01411215)
- Testing
- Enbrel
- Where
- 15 sites in China
- Volunteers
- 160 people
- Sponsor
- Pfizer
Bone Diseases, Image
Clinical Validation of BoneMRI in the Spine
BoneMRI is a quantitative 3D MRI technique that has been developed recently by MRIGuidance BV©, which is based on a multiple gradient-echo sequence and a machine learning processing pipeline.
- Conditions
- Bone Diseases, Image, Medical Device
- Trial name
- CleverBones (NCT06745791)
- Testing
- BoneMRI
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 450 people
- Sponsor
- MRIguidance B.V.
Degenerative Disc Disease
Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty
The NuBac device is indicated for reconstruction following nucleotomy in skeletally mature patients at least 18 years of age with symptomatic single level degenerative disc disease (DDD) at L4/L5 only.
- Trial name
- NCT00931515
- Testing
- NuBac, Prodisc-L
- Where
- 17 sites in United States
- Volunteers
- 30 people
- Sponsor
- Pioneer Surgical Technology, Inc.
Ankylosing Spondylitis
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis
This was a study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis
- Trial name
- ASLeap (NCT03350815)
- Testing
- 150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
- Where
- 65 sites in United States
- Volunteers
- 322 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Degenerative Disc Disease
The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
A multicenter, prospective, non-randomized, historically controlled study. To demonstrate the Synergy Disc is at least as safe and effective as conventional anterior cervical discectomy and fusion (ACDF) to treat cervical…
- Trial name
- NCT05740176
- Testing
- Anterior Cervical Discectomy and Fusion
- Where
- 23 sites in United States
- Volunteers
- 200 people
- Sponsor
- Synergy Spine Solutions
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Degenerative Disc Disease, Spondylolisthesis
Clinical Evaluation of GENEX® DS in Instrumented Posterolateral Fusion
The overall goal of this clinical study is to characterize the fusion rate of geneX® ds bone graft substitute in comparison to autograft, which is considered the gold standard for posterolateral fusion.
- Conditions
- Degenerative Disc Disease, Spondylolisthesis, Stenosis
- Trial name
- NCT02317185
- Testing
- genex bone graft with bone graft, autogenous bone graft
- Where
- 2 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Spine Wave
Degenerative Disc Disease
rhBMP-2/CRM/CD HORIZON® Spinal System Pilot Study (2-Level)
The purpose of this study is to evaluate the feasibility of using the investigational implant (rhBMP-2/CRM with the CD HORIZON® Spinal System) as a method of facilitating posterolateral lumbar spinal fusion at two adjacent…
- Trial name
- NCT01491568
- Testing
- rhBMP-2/CRM/CD HORIZON® Spinal System
- Volunteers
- 29 people
- Sponsor
- Medtronic Spinal and Biologics
Psoriatic Arthritis
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
- Trial name
- NCT03552276
- Testing
- SUNPG18_07 I (Tildrakizumab 200 mg), SUNPG18_07 II (Tildrakizumab 100 mg)
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 281 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Degenerative Disc Disease
A Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease
This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® Device using laparoscopic surgical technique as compared to an historical control group treated with Autogenous Bone/LT-CAGE® Device using…
- Trial name
- NCT01491425
- Testing
- rhBMP-2/ACS//LT-CAGE® Device, Autogenous Bone//LT-CAGE® Device
- Volunteers
- 134 people
- Sponsor
- Medtronic Spinal and Biologics
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Degenerative Disc Disease
Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
This study is designed to assess the safety and effectiveness of the rhBMP-2/ACS/LT-CAGE® device as compared to the LT-CAGE® device with autogenous bone in patients with symptomatic degenerative disc disease using an open…
- Trial name
- NCT01491386
- Testing
- rhBMP-2/ACS/LT-CAGE® Device, Autogenous Bone/LT-CAGE® Device
- Volunteers
- 279 people
- Sponsor
- Medtronic Spinal and Biologics
Juvenile Idiopahtic Arthritis
Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
This is a 8-year extension study in pediatric subjects who have been diagnosed with one of 3 subtypes of Juvenile Idiopathic Arthritis (JIA) [extended oligoarticular JIA, enthestitis related arthritis (ERA), or psoriatic…
- Trial name
- CLIPPER2 (NCT01421069)
- Testing
- etanercept
- Where
- 35 sites in Australia, Belgium and 17 more
- Volunteers
- 109 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
This was a prospective mono-country, multi-center study of the frequency of extra-axial manifestations (EAMs) in Ankylosing Spondylitis (AS) participants treated with adalimumab in routine clinical practice.
- Trial name
- AS PMOS (NCT02333383)
- Testing
- Adalimumab
- Volunteers
- 201 people
- Sponsor
- AbbVie
Cervical Degenerative Disc Disease
Post-Market Data Collection to Evaluate the Performance of the Synergy Disc®
This is a real world data collection observational study at a single site. There are both prospective and retrospective cohorts.
- Trial name
- NCT06383962
- Testing
- Synergy cervical spine disc replacement
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Synergy Spine Solutions